Imaging Integrin αvβ3 on Blood Vessels with 111In-RGD2 in Head and Neck Tumor Xenografts

@article{Terry2014ImagingI,
  title={Imaging Integrin $\alpha$v$\beta$3 on Blood Vessels with 111In-RGD2 in Head and Neck Tumor Xenografts},
  author={Samantha Y. A. Terry and K. R. Abiraj and Cathelijne Frielink and Laura K van Dijk and Johan Bussink and Wim J. G. Oyen and Otto C Boerman},
  journal={The Journal of Nuclear Medicine},
  year={2014},
  volume={55},
  pages={281 - 286}
}
Arginine-glycine-aspartic acid (RGD)–based imaging tracers allow specific imaging of integrin αvβ3, a protein overexpressed during angiogenesis, leading to the possibility that it might serve as a tool to stratify patients for antiangiogenic treatment. However, these tracers have generally been characterized in xenograft models in which integrin αvβ3 was constitutively expressed by the tumor cells themselves. In the studies presented here, the use of 111In-RGD2 as a tracer to image only… 

Figures and Tables from this paper

In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models

TLDR
All tracers showed sufficient targeting of αvβ3 integrin expression to allow for tumor detection and selection of the optimal tracer for specific diagnostic applications also depends on tumor-to-blood ratio and uptake in normal tissues; these factors should therefore also be considered.

Can 111In-RGD2 Monitor Response to Therapy in Head and Neck Tumor Xenografts?

TLDR
It is suggested that 111In-RGD2 could allow in vivo monitoring of angiogenic responses after radiotherapy and may therefore prove a good clinical tool to monitor angiogen responses early after the start of radiotherapy in patients with head and neck squamous cell carcinoma.

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

Angiogenesis is a common feature of many physiological processes and pathological conditions. RGD-containing peptides can strongly bind to integrin αvβ3 expressed on endothelial cells in neovessels

44Sc: An Attractive Isotope for Peptide-Based PET Imaging

TLDR
This study aims to develop a 44Sc-labeled RGD-based peptide for in vivo positron emission tomography (PET) imaging of integrin αvβ3 expression in a preclinical cancer model and capitalize on the relevance of this isotope as an attractive alternative isotope to more established radiometals for small molecule-based PET imaging, and as imaging surrogate of 47Sc in theranostic applications.

Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents

TLDR
This review highlights the new non-oncologic applications of RGD-based tracers and proposes that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis.

Exploration of peptide T7 and its derivative as integrin αvβ3-targeted imaging agents

TLDR
99mTc-labeled T7 and T7-6H can be regarded as promising single-photon emission computed tomography probes for imaging integrin αvβ3, and need to be further studied for noninvasive detection of tumors.

Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin αvβ3

TLDR
It is hypothesized that response to etanercept could be monitored by radionuclide imaging in arthritic mice and can be used to specifically monitor the response to therapy in experimental arthritis at the molecular level.

Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study

TLDR
This pilot study was designed to compare the distribution of 68Ga-NODAGA-RGD PET/CT for imaging αvβ3 integrins involved in tumor angiogenesis to 18F-FDGPET/CT in patients with HNSCC to find out if either has a different spatial distribution or brings different tumor information.

Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of αvβ3 Integrin Expression with Gallium-68

TLDR
The trimeric peptide homologue containing a single tris(hydroxypyridinone) chelator, [68Ga(HP3-RGD3)], clears nontarget organs and exhibits receptor-mediated uptake in mice bearing tumors and in mice with induced rheumatoid arthritis.

RGD-Binding Integrins in Head and Neck Cancers

TLDR
The current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC) is presented, with a particular focus on the arginine-glycine-aspartate (RGD)-binding integrins, in order to highlight the potential ofintegrins as targets for personalised tumour-specific identification and therapy.

References

SHOWING 1-10 OF 39 REFERENCES

Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography

TLDR
First imaging results using a small animal positron emission tomograph suggest that this compound is suitable for noninvasive determination of the α v β 3 integrin status and therapy monitoring.

Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD

TLDR
Molecular imaging with [18F]Galacto-RGD and PET can provide important information for planning and monitoring anti-angiogenic therapies targeting the αvβ3 integrins and can reveal the involvement and role of this integrin in metastatic and angiogenic processes in various diseases.

In vivo imaging of tumour angiogenesis in mice with the αvβ3 integrin-targeted tracer 99mTc-RAFT-RGD

TLDR
99mTc-RAFT-RGD allowed the in vivo imaging of αvβ3 integrin tumour expression in mice models of tumour development and indicated that intratumoural uptake preferentially occurred in angiogenic areas.

Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide.

TLDR
NODAGA-E-[c(RGDfK)]2 could be labeled rapidly with (18)F using a direct aqueous, one-pot method and it accumulated specifically in αv β3 integrin-expressing SK-RC-52 tumors, allowing for visualization by microPET.

PET imaging of αvβ3 integrin expression in tumours with 68Ga-labelled mono-, di- and tetrameric RGD peptides

TLDR
The αvβ3-binding characteristics of 68Ga-labelled monomeric, dimeric and tetrameric RGD peptides were determined and compared with their 111In-labelling counterparts and the integrin affinity and the tumour uptake followed the order of DOTA-tetramer >DOTA-dimer > Dota-monomer.

Tumor Targeting with Radiolabeled v 3 Integrin Binding Peptides in a Nude Mouse Model

TLDR
The in vivo behavior of the radiolabeled dimeric RGD peptide E-[c(RGDfK)]2 in the NIH:OVCAR-3 s.c. mice model demonstrated high and specific tumor uptake in a human tumor xenograft, and these peptides can be used for peptide receptor radionuclide imaging as well as therapy.

Monitoring Tumor Response to Antiangiogenic Sunitinib Therapy with 18F-Fluciclatide, an 18F-Labeled αVβ3-Integrin and αVβ5-Integrin Imaging Agent

TLDR
18F-fluciclatide detected changes in tumor uptake after acute antiangiogenic therapy markedly earlier than any significant volumetric changes were observable, suggesting that this imaging agent may provide clinically important information for guiding patient care and monitoring the response to antiangIogenic therapy.

Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy

TLDR
18F-AH111585 is a promising 18F-labeled RGD tracer that offers a new approach to noninvasively image tumor vasculature and may reveal important information in the assessment of the impact of antitumor therapies, in particular those that predominantly target tumor blood vessels.

Biodistribution and Pharmacokinetics of the αvβ3-Selective Tracer 18F-Galacto-RGD in Cancer Patients

TLDR
The kinetics and biodistribution of (18)F-Galacto-RGD in cancer patients shows that this tracer offers a new strategy for noninvasive monitoring of molecular processes and may supply helpful information for planning and controlling of therapeutic approaches targeting the alpha(v)beta(3) integrin.